128 related articles for article (PubMed ID: 1800003)
1. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Nishii Y; Abe J; Mori T; Brown AJ; Dusso AS; Finch J; Lopez-Hilker S; Morrissey J; Slatopolsky E
Contrib Nephrol; 1991; 91():123-8. PubMed ID: 1800003
[TBL] [Abstract][Full Text] [Related]
2. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
Brown AJ; Ritter CR; Finch JL; Morrissey J; Martin KJ; Murayama E; Nishii Y; Slatopolsky E
J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
[TBL] [Abstract][Full Text] [Related]
3. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Slatopolsky E; Finch J; Ritter C; Takahashi F
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
[TBL] [Abstract][Full Text] [Related]
4. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.
Finch JL; Brown AJ; Mori T; Nishii Y; Slatopolsky E
J Bone Miner Res; 1992 Jul; 7(7):835-9. PubMed ID: 1642151
[TBL] [Abstract][Full Text] [Related]
5. Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2).
Fan SL; Schroeder NJ; Calverley MJ; Burrin JM; Makin HL; Cunningham J
Nephrol Dial Transplant; 2000 Dec; 15(12):1943-9. PubMed ID: 11096138
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia.
Slatopolsky E; Finch J; Ritter C; Denda M; Morrissey J; Brown A; DeLuca H
Am J Kidney Dis; 1995 Nov; 26(5):852-60. PubMed ID: 7485144
[TBL] [Abstract][Full Text] [Related]
8. On the mechanisms for the selective action of vitamin D analogs.
Dusso AS; Negrea L; Gunawardhana S; Lopez-Hilker S; Finch J; Mori T; Nishii Y; Slatopolsky E; Brown AJ
Endocrinology; 1991 Apr; 128(4):1687-92. PubMed ID: 2004595
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
Funahashi H; Tanaka Y; Imai T; Wada M; Tsukamura K; Hayakawa Y; Matsuura N; Kikumori T; Oiwa M; Tominaga Y; Takagi H
J Endocrinol Invest; 1998 Jan; 21(1):43-7. PubMed ID: 9633022
[TBL] [Abstract][Full Text] [Related]
10. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
[TBL] [Abstract][Full Text] [Related]
11. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells.
Inoue D; Matsumoto T; Ogata E; Ikeda K
J Biol Chem; 1993 Aug; 268(22):16730-6. PubMed ID: 8393873
[TBL] [Abstract][Full Text] [Related]
12. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
13. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
[TBL] [Abstract][Full Text] [Related]
14. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
Tamura S; Ueki K; Mashimo K; Tsukada Y; Naitoh M; Abe Y; Kawai H; Tsuchida A; Wakamatsu R; Nojima Y
Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
[TBL] [Abstract][Full Text] [Related]
16. The effect of 22-oxacalcitriol on serum calcitriol.
Dusso AS; Negrea L; Finch J; Kamimura S; Lopez-Hilker S; Mori T; Nishii Y; Brown A; Slatopolsky E
Endocrinology; 1992 Jun; 130(6):3129-34. PubMed ID: 1597134
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.
Finch JL; Brown AJ; Kubodera N; Nishii Y; Slatopolsky E
Kidney Int; 1993 Mar; 43(3):561-6. PubMed ID: 8455354
[TBL] [Abstract][Full Text] [Related]
18. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
[TBL] [Abstract][Full Text] [Related]
19. Regulation of parathyroid hormone synthesis in chronic renal failure in rats.
Fukagawa M; Kaname S; Igarashi T; Ogata E; Kurokawa K
Kidney Int; 1991 May; 39(5):874-81. PubMed ID: 2067203
[TBL] [Abstract][Full Text] [Related]
20. The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells.
Pernalete N; Mori T; Nishii Y; Slatopolsky E; Brown AJ
Endocrinology; 1991 Aug; 129(2):778-84. PubMed ID: 1649745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
